These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2000644)

  • 41. [The genetically determined polymorphism of metabolic oxidation of the sparteine-debrisoquin type].
    Piotrovskiĭ VK; Belolipetskaia VG
    Farmakol Toksikol; 1991; 54(6):60-6. PubMed ID: 1804700
    [No Abstract]   [Full Text] [Related]  

  • 42. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study.
    Ward SA; Helsby NA; Skjelbo E; Brøsen K; Gram LF; Breckenridge AM
    Br J Clin Pharmacol; 1991 Jun; 31(6):689-92. PubMed ID: 1867963
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans.
    Schellens JH; Ghabrial H; van der Wart HH; Bakker EN; Wilkinson GR; Breimer DD
    Clin Pharmacol Ther; 1991 Nov; 50(5 Pt 1):520-8. PubMed ID: 1934865
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin.
    Brøsen K; Gram LF; Kragh-Sørensen P
    Ther Drug Monit; 1991 Mar; 13(2):177-82. PubMed ID: 2053127
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)--increased Michaelis is Constant (Km) and loss of stereoselectivity of bufuralol 1'-hydroxylation in poor metabolizers.
    Dayer P; Gasser R; Gut J; Kronbach T; Robertz GM; Eichelbaum M; Meyer UA
    Biochem Biophys Res Commun; 1984 Nov; 125(1):374-80. PubMed ID: 6508804
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes.
    Dahl-Puustinen ML; Alm C; Bertilsson L; Christenson I; Ostman J; Thunberg E; Wikström I
    Br J Clin Pharmacol; 1990 Sep; 30(3):476-80. PubMed ID: 2121211
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes.
    Breyer-Pfaff U; Pfandl B; Nill K; Nusser E; Monney C; Jonzier-Perey M; Baettig D; Baumann P
    Clin Pharmacol Ther; 1992 Oct; 52(4):350-8. PubMed ID: 1424408
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cytochrome-P450-dependent hydroxylation in cluster headache.
    Tomson T; Waldenlind E; Ekbom K
    Cephalalgia; 1992 Jun; 12(3):161-4. PubMed ID: 1623511
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland.
    Brosen K
    Drug Metab Pers Ther; 2015 Sep; 30(3):147-63. PubMed ID: 25719307
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Debrisoquin oxidation polymorphism in a Spanish population.
    Benítez J; LLerena A; Cobaleda J
    Clin Pharmacol Ther; 1988 Jul; 44(1):74-7. PubMed ID: 3391005
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proguanil metabolism in relation to S-mephenytoin oxidation in a Turkish population.
    Basci NE; Bozkurt A; Kortunay S; Isimer A; Sayal A; Kayaalp SO
    Br J Clin Pharmacol; 1996 Dec; 42(6):771-3. PubMed ID: 8971434
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine.
    Wanwimolruk S; Chalcroft S
    Br J Clin Pharmacol; 1991 Nov; 32(5):617-20. PubMed ID: 1954076
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype.
    Wan J; Xia H; He N; Lu YQ; Zhou HH
    Br J Clin Pharmacol; 1996 Oct; 42(4):471-4. PubMed ID: 8904619
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The importance of examining genetic polymorphism of drug oxidation in psychiatry].
    Beszłej JA; Kiejna A
    Psychiatr Pol; 1995; 29(1):45-56. PubMed ID: 7878153
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dextromethorphan and debrisoquine metabolism and polymorphism of the gene for cytochrome P450 isozyme 2D50 in Thoroughbreds.
    Corado CR; McKemie DS; Knych HK
    Am J Vet Res; 2016 Sep; 77(9):1029-35. PubMed ID: 27580115
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Human cytochromes P450: evolution, catalytic activities and interindividual variations in expression.
    Gonzalez FJ; Gelboin HV
    Prog Clin Biol Res; 1991; 372():11-20. PubMed ID: 1956910
    [No Abstract]   [Full Text] [Related]  

  • 57. The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects.
    Eichelbaum M; Gross AS
    Pharmacol Ther; 1990; 46(3):377-94. PubMed ID: 2188269
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genetic polymorphisms of drug metabolism.
    Meyer UA
    Fundam Clin Pharmacol; 1990; 4(6):595-615. PubMed ID: 1982880
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Genetic polymorphism in human drug metabolism].
    Yamazoe Y; Nagata K
    Nihon Yakurigaku Zasshi; 1993 Feb; 101(2):69-77. PubMed ID: 8454228
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers.
    Llerena A; Dahl ML; Ekqvist B; Bertilsson L
    Ther Drug Monit; 1992 Jun; 14(3):261-4. PubMed ID: 1412613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.